MC38 Orthotopic Mouse Model Service for Colon Cancer

The MC38 orthotopic mouse model stands as one of the most extensively utilized syngeneic platforms for dissecting colorectal carcinoma biology and interrogating novel therapeutic modalities within an intact immune microenvironment. Alfa Cytology engineers this model with surgical exactitude and quality-controlled cell assets, providing researchers with a dependable foundation for immunotherapy screening, combination regimen benchmarking, and mechanistic exploration of tumor-immune dynamics in the preclinical space.

Overview of MC38 Orthotopic Mouse Model for Colon Cancer

The MC38 cell line was originally established from a colon adenocarcinoma that arose in a C57BL/6 mouse following chronic exposure to the chemical carcinogen 1,2-dimethylhydrazine dihydrochloride (DMH). This murine-derived line carries a substantial mutational burden, including p53 mutation and KRAS wild-type status, which collectively render it moderately immunogenic and highly responsive to immune checkpoint blockade in vivo. When established orthotopically within the cecal wall, MC38 tumors faithfully recapitulate the histopathological architecture of human colorectal adenocarcinoma, exhibiting glandular differentiation, robust neoangiogenesis, and progressive infiltration by host immune populations including CD8+ cytotoxic T lymphocytes, regulatory T cells, and myeloid-derived suppressor cells.

Fig 1. Temporal evolution of the MC38 tumor microenvironment from early (Day 7) to late-stage (Day 21) disease, characterized by CD31+ vascular remodeling, reticulin fiber deposition, and progressive CD3+ T-cell infiltration patterns, providing critical guidance for optimal therapeutic intervention timepoint selection in preclinical immuno-oncology studies. (Shields, Nicholas J., et al., 2023)

The orthotopic cecal implantation strategy offers a decisive advantage over flank-based approaches by situating tumors within the authentic colonic mucosa and submucosal layers, thereby preserving the luminal microbiome interface, mesenteric lymphatic drainage, and peritoneal dissemination routes characteristic of clinical disease progression. This anatomical fidelity supports spontaneous metastasis to regional lymph nodes, liver, and lung, while the syngeneic C57BL/6 background permits interrogation of endogenous anti-tumor immunity, checkpoint inhibitor efficacy, and tumor microenvironment remodeling in vivo without the confounding effects of xenogeneic immune incompatibility. Consequently, the MC38 orthotopic model serves as a cornerstone for preclinical evaluation of PD-1/PD-L1 antagonists, CTLA-4 blockade, cancer vaccines, and adoptive cellular therapies in colorectal malignancy.

Cell Line Information: MC38

The table below presents a detailed compilation of the biological, genetic, and technical attributes of the MC38 murine colon adenocarcinoma cell line, serving as a reference framework for experimental design and data interpretation in both in vitro and in vivo settings.

Our Services

Alfa Cytology offers a meticulously orchestrated MC38 orthotopic mouse model service that spans the entire preclinical study lifecycle—from authenticated cell line expansion and mycoplasma clearance through cecal wall surgical implantation, longitudinal tumor monitoring via bioluminescence or caliper measurement, and comprehensive endpoint histopathological and flow cytometric analysis. Our technical staff calibrate every protocol parameter to your compound class and mechanism of action, ensuring that tumor growth trajectories, immune infiltration patterns, and therapeutic response windows align with the translational questions driving your research program.

Workflow of MC38 Orthotopic Mouse Model Construction

Construction of the MC38 orthotopic colon cancer model demands precise surgical technique and stringent quality control to achieve consistent engraftment while safeguarding animal welfare. The protocol described below represents a standardized framework executed under specific pathogen-free conditions, with each stage designed to maximize reproducibility and biological relevance in vivo. The workflow proceeds through the following stages:

1. Cell Line Revival and Quality Assurance: MC38 cells are thawed from authenticated cryopreserved stocks and expanded in DMEM supplemented with 10% FBS under standard growth conditions. Prior to surgical use, cells undergo mandatory STR identity verification, mycoplasma PCR screening, and viability quantification by trypan blue exclusion to confirm a live-cell fraction exceeding 95%. For studies requiring longitudinal in vivo imaging, luciferase- or GFP-expressing MC38 derivatives are prepared according to the same quality criteria.
2. Host Selection and Environmental Acclimation: Female or male C57BL/6 mice aged 6–9 weeks are selected to ensure genetic syngeneity and immune competence. Animals are housed in specific pathogen-free vivaria with controlled temperature (22 ± 2°C), humidity (50 ± 10%), and a 12-hour light/dark cycle. A minimum acclimation period of five days is observed, during which baseline body weights and clinical observations are recorded to establish preoperative health baselines.
3. Anesthesia and Surgical Site Preparation: On the day of implantation, mice are anesthetized with 2–3% isoflurane delivered via nose cone, with depth of anesthesia confirmed by absence of pedal withdrawal reflex. The ventral abdominal wall is shaved and sterilized sequentially with povidone-iodine and 70% ethanol. Aseptic drapes are applied to maintain a sterile operative field throughout the procedure.
4. Cecal Exteriorization and Cell Inoculation: A 1.0–1.5 cm midline laparotomy is performed to expose the abdominal cavity. The cecum is gently exteriorized using sterile cotton-tipped applicators and kept moist with warm sterile PBS. A suspension of 2 × 10⁵ to 2 × 10⁶ viable MC38 cells in 25–50 µL of HBSS or serum-free DMEM is drawn into a 1 mL syringe fitted with a 30 G needle. The needle is inserted into the subserosal layer of the cecal wall at the anti-mesenteric border, and the cell suspension is delivered slowly to form a visible bleb without penetrating the mucosal surface.
5. Hemostasis and Abdominal Closure: The injection site is compressed gently with a sterile cotton swab for approximately 3 minutes to prevent leakage and promote hemostasis. The cecum is inspected for integrity and then returned to the peritoneal cavity in anatomical orientation. The abdominal wall musculature is closed with absorbable 5-0 sutures, and the skin incision is sealed with surgical staples or tissue adhesive. Mice are transferred to a warmed recovery chamber and monitored until full ambulation is restored.
6. Postoperative Care and Tumor Surveillance: During the immediate postoperative period, mice receive analgesia according to institutional guidelines and are monitored daily for wound integrity, body weight, and clinical score. Tumor establishment is tracked twice weekly beginning approximately 7 days post-implantation. For luciferase-expressing MC38 lines, tumor burden is quantified in vivo via IVIS bioluminescence imaging following intraperitoneal luciferin administration. Conventional cohorts are monitored by abdominal palpation and digital caliper measurement of externally palpable masses.
7. Cohort Randomization and Therapeutic Intervention: Upon reaching a predetermined tumor signal intensity or palpable volume—typically 10–14 days post-implantation—mice are randomized into treatment arms using stratified allocation based on tumor burden and body weight. Investigational agents are administered according to predefined dosing regimens, with route and frequency tailored to pharmacokinetic properties and mechanism of action. Vehicle control groups receive matched formulation on an identical schedule.
8. Necropsy and Multi-Parametric Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised en bloc, weighed, and photographed. Tumor tissue is subdivided for formalin fixation and paraffin embedding (H&E, IHC for CD8, FoxP3, Ki-67, CD31), snap-freezing for Western blot or RNA-seq, and dissociation into single-cell suspensions for flow cytometric immunophenotyping. Metastatic foci in mesenteric lymph nodes, liver, lung, and peritoneum are enumerated macroscopically and confirmed histologically.

Fig 2. MC38 Orthotopic Mouse Model construction workflow.

Case Study-MC38 Orthotopic Mouse Model Development

In a recent preclinical program, the MC38 orthotopic model was leveraged to assess the anti-tumor activity of a novel bispecific antibody engaging both PD-1 and LAG-3 immune checkpoints. Following cecal wall implantation of luciferase-expressing MC38 cells, tumor-bearing C57BL/6 mice were randomized and treated with the bispecific construct, single-agent anti-PD-1, or isotype control. Longitudinal in vivo bioluminescence imaging demonstrated marked suppression of tumor photon flux in the bispecific arm relative to monotherapy and vehicle groups. Post-treatment flow cytometric analysis of dissociated tumor tissue revealed elevated CD8+ T cell infiltration and reduced FoxP3+ regulatory T cell abundance in the combination-targeting cohort. Histological examination further confirmed increased apoptotic indices and diminished microvessel density within treated tumors. These observations highlight the capacity of the MC38 orthotopic platform to discriminate subtle differences in immunotherapeutic potency and to generate mechanistic insights into tumor microenvironment modulation in vivo.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your partner for MC38 orthotopic model development ensures access to a technically refined service ecosystem engineered for immunotherapy-focused preclinical research. Our operational differentiators include:

• Syngeneic model expertise with authenticated MC38 cell stocks maintained under rigorous passage control and mycoplasma surveillance to preserve immunogenic phenotype and checkpoint inhibitor responsiveness in vivo.
• Skilled microsurgical teams proficient in cecal wall orthotopic implantation, achieving high tumor take rates with minimal perioperative mortality and rapid postoperative recovery.
• Integrated bioluminescence and fluorescence imaging infrastructure for non-invasive longitudinal tumor tracking in vivo, enabling real-time assessment of therapeutic response and metastatic progression.
• Customizable study architectures spanning monotherapy, combination, and sequential dosing paradigms, with flexible randomization stratification and blinded endpoint evaluation.
• Comprehensive immune profiling capabilities including multi-color flow cytometry of tumor-infiltrating lymphocytes, myeloid subsets, and checkpoint expression panels.
• Streamlined project timelines with dedicated scientific liaisons who provide transparent milestone updates, adaptive protocol refinement, and publication-ready data compilation.

Contact Us

Whether you are advancing a first-in-class immunotherapy candidate or refining a combination regimen against colorectal malignancy, the MC38 orthotopic model offers an indispensable preclinical window into tumor-immune interplay. The team at Alfa Cytology is ready to architect a tailored study plan that meets your scientific and regulatory objectives. Reach out to us today to initiate project scoping, receive a customized proposal, or arrange a technical consultation with our oncology model specialists.

For research use only. Not intended for any clinical use.